Laboratory Co. of America Holdings (NYSE:LH) EVP Amy B. Summy Sells 758 Shares

Laboratory Co. of America Holdings (NYSE:LH) EVP Amy B. Summy sold 758 shares of the firm’s stock in a transaction dated Friday, March 28th. The stock was sold at an average price of $231.67, for a total value of $175,605.86. Following the completion of the transaction, the executive vice president now owns 5,302 shares of the company’s stock, valued at approximately $1,228,314.34. This represents a 12.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Laboratory Co. of America Price Performance

Shares of Laboratory Co. of America stock opened at $232.63 on Wednesday. The stock has a market capitalization of $19.47 billion, a price-to-earnings ratio of 26.38, a price-to-earnings-growth ratio of 1.71 and a beta of 1.12. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $258.59. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. The company has a fifty day moving average of $244.45 and a 200-day moving average of $234.86.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. Equities research analysts expect that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Thursday, February 27th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend was Thursday, February 27th. Laboratory Co. of America’s payout ratio is currently 32.65%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LH shares. UBS Group cut their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Bank of America upped their price target on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a report on Friday, December 13th. StockNews.com lowered Laboratory Co. of America from a “buy” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group upped their target price on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, Citigroup upgraded Laboratory Co. of America from a “neutral” rating to a “buy” rating and lifted their price target for the company from $250.00 to $300.00 in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $269.92.

Hedge Funds Weigh In On Laboratory Co. of America

A number of institutional investors and hedge funds have recently made changes to their positions in LH. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Laboratory Co. of America in the 4th quarter worth approximately $25,929,000. Jefferies Financial Group Inc. boosted its holdings in Laboratory Co. of America by 156.9% in the fourth quarter. Jefferies Financial Group Inc. now owns 25,513 shares of the medical research company’s stock worth $5,851,000 after acquiring an additional 15,582 shares in the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of Laboratory Co. of America in the fourth quarter worth $44,000. Forum Financial Management LP increased its holdings in shares of Laboratory Co. of America by 93.9% during the fourth quarter. Forum Financial Management LP now owns 2,461 shares of the medical research company’s stock valued at $564,000 after acquiring an additional 1,192 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Laboratory Co. of America in the 4th quarter worth about $481,000. Institutional investors own 95.94% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.